ГК «Росатом» помог возобновить поставки радиофармпрепарата для диагностики нейробластомы 123I-МИБГ

The final product is manufactured at the Radium Institute

JSC "V/O "Isotop" (part of Rosatom State Corporation), together with the Khlopin Radium Institute and the Russian Scientific Center of Radiology and Surgical Technologies named after Granov, have resumed weekly deliveries of the radiopharmaceutical 123I-MIBG (metaiodobenzylguanidine) to medical institutions in Moscow. This radiopharmaceutical is designed to assess the functional state of the sympathetic nervous system and diagnose neuroblastoma in young children.

The promptness of 123I-MIBG deliveries is of particular importance, as the drug contains iodine-123, a short-lived isotope with a short half-life. In early 2023, the production of raw materials for this drug in Moscow was suspended due to technical problems.

Thanks to the support of the Russian Scientific Center of Radiology and Surgical Technologies named after Granov, we were able to start irradiating targets for the production of iodine-123, from which we then produce the final product at the Radium Institute. Now, a special transport of JSC "V/O "Isotop" departs from the institute every week, which promptly delivers the finished radiopharmaceutical to medical institutions in Moscow, without requiring additional processing on site
Konstantin Vergazov, General Director of the Radium Institute

Read more on the topic:

Russia has developed drugs for spinal muscular atrophy and Bekhterev's disease

Russia is import-substituting high-precision radioisotope devices

Rosatom has developed a new technology for producing a drug for cancer treatment

Now on home